A Potential New Therapy for Dermatomyositis: Findings from the VALOR Study скачать в хорошем качестве

A Potential New Therapy for Dermatomyositis: Findings from the VALOR Study

Dr. Michelle Min, Director of Rheumatologic Dermatology at UC Irvine Health, shares results from the VALOR study, which tested an investigational, once-daily oral medication called brepocitinib for adults with dermatomyositis (DM). In this year-long study, patients taking brepocitinib experienced meaningful improvements in muscle strength, skin symptoms, and overall function compared to placebo. Many were even able to reduce or stop steroid use — a major step forward for long-term care. This is the first time a medicine has shown such strong results in a year-long, placebo-controlled trial for dermatomyositis — a rare autoimmune disease that affects both the muscles and the skin. Learn more about progress in dermatomyositis research at dermatomyositis.com. Timestamps: 00:00 – Introduction: Dr. Michelle Min, UC Irvine 00:23 – What is brepocitinib, a new dermatomyositis medicine? 00:50 – Encouraging VALOR study results 01:23 – VALOR study summary 01:48 – About brepocitinib and what’s next #Dermatomyositis #DermatomyositisTreatment #DermatomyositisResearch #DermatomyositisCommunity #ClinicalTrial #AutoimmuneDisease #HopeInScience